



July 29, 2026

6:30PM-8PM

Pharmacy & Therapeutics Committee Meeting

Formulary and Program Updates
Effective 10/1/2026



Roll Call

P&T COMMITTEE MEMBERS

David Konanc, MD

Jennifer Burch, PharmD, CDE

Ghassan Al-Sabbagh, MD

W. Russell Laundon, PharmD, MS, BCPS

Timothy Ashley, MD, MPH

Garland Moeller, MD

Stephen Hsieh, MD

Susan Moore, MD

PLAN STAFF & VENDORS

State Health Plan

- Tom Friedman, Executive Director
- Caroline Smart, Deputy Executive Administrator
- Jenny Vogel, PharmD, Sr. Clinical Pharmacist
- Toni Prine, RPh, Director of Pharmacy Operations, Pharmacy Benefits
- Justin Wylie, Web Designer

CVS Caremark

- Renée Jarnigan, RPh, Clinical Advisor

Ethics Awareness & Conflict of Interest Reminder

In accordance with the [Recusal Guidelines for Public Servants](#), it is the duty of every member of the Pharmacy & Therapeutics Committee, whether serving in a vote casting or advisory capacity, to avoid both conflicts of interest and appearances of conflict.

Does any Committee member have any known conflict of interest or the appearance of any conflict with respect to any manufacturers of any medication to be discussed at today's meeting?

Or, if during the course of the evaluation process if you identify a conflict of interest or the appearance of a conflict.

If so, please identify the conflict or appearance of conflict and refrain from any undue participation in the particular matter involved.

Minutes from Previous Committee Meeting

Instead of reading the minutes, copies were distributed prior to the meeting for your review.

- Are there any additions or corrections to the minutes?
- If not, the minutes will stand approved as is.



Executive Update

Proposed Formulary Updates – Effective 10/1/2026

Quarterly Formulary Updates:

- Formulary Additions (including new molecular entities, additions, add backs and line extensions)
- Utilization Management
- Product Exclusions
- Tier Changes (Downtiers/Uptiers)

Presented by:

- Renée Jarnigan, RPh, Clinical Advisor, CVS Health
- Jenny Vogel, PharmD, Sr. Clinical Pharmacist, North Carolina State Health Plan

Formulary Updates – New Molecular Entities

Formulary Additions

- These are new formulary medications for the State Health Plan that are eligible for formulary inclusion as the CVS new drug to market block strategy has been satisfied.

Drug	Indication	Criteria for Approval	Projected Annual Utilizers	Tier
Revuforj (revumenib) oral tablets	Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A (KMT2A) translocation in adult and pediatric patients 1 year and older.	SGM QL	< 5	6

Formulary Update- Biosimilar Additions

Formulary Additions

- All Drugs, including line extensions, new formulations of existing formulary products and add backs (products not new to market that were previously blocked by the Plan and are now added to the formulary).

Therapeutic Category	Biosimilar Drug	Reference Product	Projected Annual Utilizers	Tier
Central Nervous System, Multiple Sclerosis	Tyruko (natalizumab-sztn) intravenous injection	Tysabri (natalizumab)	< 5	4
Central Nervous System, Myasthenia Gravis	Epysqli (eculizumab-aagh) intravenous injection	Soliris (eculizumab)	< 5	4

Formulary Updates- Additions

Formulary Additions

- All Drugs, including line extensions, new formulations of existing formulary products and add backs (products not new to market that were previously blocked by the Plan and are now added to the formulary).

Therapeutic Category	Drug	Projected Annual Utilizers	Tier
Central Nervous System, Antipsychotics	Invega Hafyera (paliperidone) intramuscular injection	10	2
Central Nervous System, Antipsychotics	Invega Trinza (paliperidone) intramuscular injection	10 – 20	2
Central Nervous System, Multiple Sclerosis	Briumvi (ublituximab-xiiy) intravenous injection	30-75	5

Formulary Updates- Add Backs

Formulary Additions

- All Drugs, including line extensions, new formulations of existing formulary products and **add backs** (products not new to market that were previously blocked by the Plan and are now added to the formulary).

Therapeutic Category	Drug	Projected Annual Utilizers	Tier
Vasomotor Symptom Agents, Non-Hormonal	paroxetine mesylate 7.5mg capsules	400	1

Formulary Updates – Line Extensions

Formulary Additions

- All Drugs, including **line extensions**, new formulations of existing formulary products and add backs (products not new to market that were previously blocked by the Plan and are now added to the formulary).

Therapeutic Category	Drug	Tier
Immunologic Agents/ Hereditary Angioedema	Orladeyo (berotralstat) oral pellets	5
Cardiovascular/ Aldosterone Receptor Antagonists	Kerendia (finerenone) 40 MG oral tablets	2

Formulary Updates – Additions

Questions?

Formulary Updates – Product Exclusions

Standard Control Formulary – Exclusions

- Removals of certain high-cost drugs such as multisource brands that have lower cost generic alternatives available or other clinically effective lower cost options.

Formulary Exclusion Exception Process:

- This process is available to support Plan members who, per their provider, have a medical necessity to remain on an excluded drug.
- There may be circumstances in which the formulary alternatives may not be appropriate for some members. In this case, a member may be approved for the excluded drug with an exception process.
- An exception is defined as a situation where the member has tried and failed (that is, had an inadequate treatment response or intolerance) to the required number of formulary alternatives; or the member has a documented clinical reason such as an adverse drug reaction or drug contraindication that prevents them from trying the formulary alternatives.
- If a member's exception is approved that drug will be placed into Tier 3 or Tier 6 and the member will be subject to the applicable cost share.

Formulary Updates – Product Exclusions

Therapeutic Category	Drug	# Utilizers (6 mo.)	Formulary Preferred Alternatives
Central Nervous System, Multiple Sclerosis	Tysabri (natalizumab) intravenous injection	4	Tyruko (natalizumab-sztn)
Hematologic, Paroxysmal Nocturnal Hemoglobinuria (PNH) Agents	Soliris* (eculizumab) intravenous injection	1	Epysqli (eculizumab-aagh)
Topical/Dermatology, Antifungals	Ecoza (econazole nitrate) topical foam	0	ciclopirox, clotrimazole, econazole, ketoconazole cream 2%, naftifine
Topical/Dermatology, Local Anesthetics	Ztlido (lidocaine) topical patch	8	lidocaine patch

*NOTE: This change represents full exclusion; currently only excluded for the myasthenia gravis indication.

Formulary Updates – Exclusions

Questions?

Formulary Updates – Downtiers

Movement to Preferred Status

- Typically, branded medications that are added as preferred products to provide additional treatment options.
- All the following products will be moving from a higher tier to a lower tier.

Therapeutic Category	Drug	Current Utilizers	Tier Change
Central Nervous System, Antipsychotics	Invega Sustenna (paliperidone) intramuscular injection	28	3 → 2

Formulary Updates – Uptiers

Movement to Non-preferred Status

- Typically, branded medications that have readily available generic alternatives, biosimilars or other preferred formulary alternatives in the therapeutic class.
- All the following products will be moving from a lower tier to a higher tier.

Therapeutic Category	Drug	Current Utilizers	Tier Change
Autoimmune Agents, Self-Administered	Orencia (abatacept) subcutaneous solution 50MG/0.4ML and 87.5MG/0.7ML	186	5 → 6
Central Nervous System, Antipsychotics	Perseris (risperidone) intramuscular injection	1	2 → 3

Formulary Updates – Downtiers/Uptiers

Questions?

Summary of Formulary Changes Effective 10/1/2026

NEW MOLECULAR ENTITIES

- 1 new drug products were added to the formulary

OTHER FORMULARY ADDITIONS

- 8 additional products were added to the formulary

UTILIZATION MANAGEMENT

- SGM/Specialty QL for REVUFORJ

PRODUCT EXCLUSIONS

- 4 products were excluded

DOWNTIERS/UPTIERS

- 3 products had tier movements

New Business?

Upcoming Meeting Dates for 2026

- **Wednesday, September 30, 2026**



Thank You.

